The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) was developed for use in clinical trials and longitudinal patient assessment. To characterize disease severity using the CDASI and assess responsiveness of this instrument to ...

We conducted a thorough literature search using PubMed for studies validating and utilizing the CDASI between 2008, when it was first developed, and October 2018. Articles in this review pertain to development and validation, use in therapeutic evaluation, monitoring of disease progression, quality of life, and relationship with biomarkers.

Objective: To characterize disease course in treated cutaneous DM by using the Cutaneous Dermatomy-ositis Disease Area and Severity Index (CDASI), a validated outcome instrument. Methods: A retrospective cohort included patients with DM who had their CDASI activity subscore recorded for at least 2 years.

The CDASI, developed by Dr. Victoria Werth and colleagues, is a clinician- scored single page instrument that separately measures activity and damage in the skin of dermatomyositis patients for use in clinical practice or clinical/therapeutic studies. The modified CDASI (version 2) is the one in current use.

Access up-to-date information on the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI): copyright, licensing, scoring, translations, ...

Ten dermatologists evaluated 14 patients with DM using the CDASI, CAT-BM, and PGA scales. Inter- and intra-rater reliability, validity, responsiveness, and completion time were compared for each outcome instrument. Responsiveness was assessed from a different study population, where one physician evaluated 35 patients with 110 visits.

2023年6月16日 · Five of the six DM trials in the past decade included measures of skin disease activity, and the majority used change in Cutaneous Dermatomyositis Disease Area and Severity Index Activity score (CDASI-A) as a secondary effi-cacy outcome. The CDASI-A is a reliable DM skin specific. 2023 The Authors.

The CDASI is a valid and responsive measure that can be used to characterize cutaneous dermatomyositis severity and detect improvement in disease activity. Variations in cut-offs may be due to differences in disease severity between the two populations or inter-rater variations in the use of the ext …

Previous studies have shown that skin disease in dermatomyositis (DM) is best assessed using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI). Although the CDASI has been validated for use by dermatologists, it has not been ...

(CDASI) The CDASI is an outcome measure designed to assess cutaneous DM disease activity and damage. Disease involvement is rated in 15 different anatomical locations using multiple activity and damage measures. Activity and Damage Subscale scores range from 0 to 100 and 0 to 32, respectively, where higher scores indicate greater disease severity.